Parallel Bio Secures $21 Million in Series A to Advance Human-First Drug Discovery
Signs on Eight Pharmaceutical Partners and Completes First Preclinical Study from Immune Organoid Platform with Centivax CAMBRIDGE, Mass.–(BUSINESS WIRE)–Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series…